Troglitazone API Manufacturers

Looking for Troglitazone API 97322-87-7?

Description:

Here you will find a list of producers, manufacturers and distributors of Troglitazone. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Troglitazone 

Cas Number:

97322-87-7 

DrugBank number:

DB00197 

Unique Ingredient Identifier:

I66ZZ0ZN0E

Troglitazone is a type of Glitazones

Glitazones, also known as thiazolidinediones (TZDs), are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the treatment of type 2 diabetes mellitus. These compounds act as insulin sensitizers, enhancing the body's response to insulin, thereby promoting glucose utilization and regulating blood sugar levels.

Glitazones exert their therapeutic effects by activating the peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor found predominantly in adipose tissue. PPAR-γ activation leads to improved insulin sensitivity in adipocytes, skeletal muscle cells, and hepatocytes, resulting in decreased hepatic glucose production and increased glucose uptake in peripheral tissues.

The primary glitazone medications available in the market include rosiglitazone and pioglitazone. These drugs are administered orally and are typically prescribed in conjunction with other antidiabetic medications, such as metformin or sulfonylureas, to achieve optimal glycemic control.

Glitazones are characterized by their high specificity for PPAR-γ receptors, which distinguishes them from other antidiabetic drug classes. However, their use may be associated with certain adverse effects, such as weight gain, fluid retention, and an increased risk of heart failure. Therefore, close monitoring and individual patient assessment are essential when prescribing glitazones.

In conclusion, glitazones are a valuable class of pharmaceutical APIs utilized in the management of type 2 diabetes. Their ability to enhance insulin sensitivity through PPAR-γ activation makes them an effective therapeutic option, albeit with potential side effects that require careful consideration in clinical practice.

Troglitazone (Glitazones), classified under Anti-diabetics

Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.

Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.

Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.

These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.

It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.

In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.

• Shandong Octagon Chemicals Limited from China, product country of origin China

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.